[{"id":"18a1a3bc-cb86-4ec3-a940-d74393ef141c","acronym":"STAMINA-01","url":"https://clinicaltrials.gov/study/NCT05205109","created_at":"2024-02-20T18:31:22.397Z","updated_at":"2025-02-25T16:17:13.696Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05205109 - STAMINA-01","lead_sponsor":"Antengene Therapeutics Limited","biomarkers":" CD73","pipe":" | ","alterations":" CD73 expression","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2024-04-30"},{"id":"4bdc6995-4092-4a59-a2d4-49ba4544cf90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05338580","created_at":"2022-04-21T15:55:23.863Z","updated_at":"2024-07-02T16:35:09.726Z","phase":"Phase 2","brief_title":"Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05338580","lead_sponsor":"TJ Biopharma Co., Ltd.","biomarkers":" PD-L1 • CD276 • CD73","pipe":" | ","alterations":" PD-L1 expression • CD73 expression","tags":["PD-L1 • CD276 • CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enoblituzumab (MGA271)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/31/2023","start_date":" 12/31/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-04-15"},{"id":"ab53141c-faa5-4818-bfa6-8bc2baf852f9","acronym":"DOSa","url":"https://clinicaltrials.gov/study/NCT04668300","created_at":"2024-04-15T18:24:09.850Z","updated_at":"2024-07-02T16:35:09.706Z","phase":"Phase 2","brief_title":"Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma","source_id_and_acronym":"NCT04668300 - DOSa","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD8 • PD-1 • CD73 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD73 expression","tags":["PD-L1 • CD8 • PD-1 • CD73 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-15"},{"id":"e9745708-7929-4504-9e2d-4c705c19fc86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03611556","created_at":"2023-10-04T01:11:28.511Z","updated_at":"2024-07-02T16:35:34.886Z","phase":"Phase 1b/2","brief_title":"MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.","source_id_and_acronym":"NCT03611556","lead_sponsor":"MedImmune LLC","biomarkers":" NT5E","pipe":" | ","alterations":" CD73 expression","tags":["NT5E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 07/22/2022","primary_completion_date":" 07/22/2022","study_txt":" Completion: 07/22/2022","study_completion_date":" 07/22/2022","last_update_posted":"2023-10-03"},{"id":"ed45cc8a-5b1f-4212-bf7f-555eb5b9a4a1","acronym":"LUNGadenosine","url":"https://clinicaltrials.gov/study/NCT05648188","created_at":"2022-12-13T14:58:00.644Z","updated_at":"2024-07-02T16:35:59.218Z","phase":"","brief_title":"A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells","source_id_and_acronym":"NCT05648188 - LUNGadenosine","lead_sponsor":"Centre Hospitalier Universitaire de Nice","biomarkers":" NT5E • ENTPD1","pipe":" | ","alterations":" CD73 expression • ENTPD1 expression","tags":["NT5E • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression • ENTPD1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2022-12-13"}]